Corticortophin releasing factor 2 receptor agonist treatment significantly slows disease progression in mdx mice

BACKGROUND: Duchenne muscular dystrophy results from mutation of the dystrophin gene, causing skeletal and cardiac muscle loss of function. The mdx mouse model of Duchenne muscular dystrophy is widely utilized to evaluate the potential of therapeutic regimens to modulate the loss of skeletal muscle...

Descripción completa

Detalles Bibliográficos
Autores principales: Hinkle, Richard T, Lefever, Frank R, Dolan, Elizabeth T, Reichart, Deborah L, Dietrich, Jefferey A, Gropp, Kathryn E, Thacker, Robert I, Demuth, Jeffrey P, Stevens, Paula J, Qu, Xiaoyan A, Varbanov, Alex R, Wang, Feng, Isfort, Robert J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1936998/
https://www.ncbi.nlm.nih.gov/pubmed/17626629
http://dx.doi.org/10.1186/1741-7015-5-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1936998/
https://www.ncbi.nlm.nih.gov/pubmed/17626629
http://dx.doi.org/10.1186/1741-7015-5-18

Ejemplares similares